PARIS–(BUSINESS WIRE)–Regulatory News: GenSight Biologics (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma company focused on developing and commercializing innovative gene therapies for retinal neurodegenerative diseases and cent…
Author: Business Wire
GenSight Biologics annonce les résultats de son Assemblée Générale Extraordinaire du 28 janvier 2026
PARIS–(BUSINESS WIRE)–Regulatory News: GenSight Biologics (Euronext : SIGHT, ISIN : FR0013183985, éligible PEA-PME), société biopharmaceutique dédiée au développement et à la commercialisation de thérapies géniques innovantes pour le traitement des m…
Glaukos Announces US FDA Approval of NDA Supplement Allowing for Re-Administration of iDose® TR
ALISO VIEJO, Calif.–(BUSINESS WIRE)–Glaukos Corporation (NYSE: GKOS), an ophthalmic pharmaceutical and medical technology focused on novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases, today announced that the U.S….
Drug Farm Announces FDA Fast Track Designation for First-in-Class ALPK1 Inhibitor DF-003 for the Treatment of ROSAH Syndrome
ALBANY, N.Y. & SHANGHAI–(BUSINESS WIRE)–FDA fast tracks DF-003 for ROSAH syndrome, announces Drug Farm.
Personalized Ophthalmology Therapies Market Report 2025: $5.46 Bn Opportunities, Trends, Competitive Landscape, Strategies, and Forecasts, 2019-2024, 2024-2029F, 2034F – ResearchAndMarkets.com
DUBLIN–(BUSINESS WIRE)–The “Personalized Ophthalmology Therapies Market Report 2025” has been added to ResearchAndMarkets.com’s offering. The personalized ophthalmology therapies market is experiencing significant growth, with an expected increase fr…
Following Merger, Advancing Sight Network and Miracles In Sight Become Precision Ocular Network
BIRMINGHAM, Ala. & CLEMMONS, N.C.–(BUSINESS WIRE)–Advancing Sight Network and Miracles In Sight today announced Precision Ocular Network as the new name and brand of their combined organization, following the merger unveiled in November. The new iden…
Johnson & Johnson Marks $100 Million of MedTech Products Donated Since 2020 to Help People Live, See and Smile
NEW BRUNSWICK, N.J.–(BUSINESS WIRE)–Johnson & Johnson, with support from the Johnson & Johnson (J&J) Foundation, announced that it has donated $100 million of MedTech products since 2020 to help more people around the world access the spe…
Qlaris Bio Appoints Robert Warner to Board of Directors
DEDHAM, Mass.–(BUSINESS WIRE)–Qlaris Bio, Inc., a clinical-stage biotechnology company focused on developing first-in-class therapies for glaucoma, today announced the appointment of Robert Warner to its board of directors. Mr. Warner’s appointment c…
Novaliq Receives FDA IND Clearance to Advance NOV05 in a Phase II Clinical Trial in Non-infectious Anterior Uveitis
HEIDELBERG, Germany & CAMBRIDGE, Mass.–(BUSINESS WIRE)– #FDA–Novaliq, a biopharmaceutical company focusing on first- and best-in-class ocular therapeutics based on its unique water-free EyeSol® drug category, today announced that the U.S. Food and D…
Johnson & Johnson reports Q4 and Full-Year 2025 results
NEW BRUNSWICK, N.J.–(BUSINESS WIRE)–Johnson & Johnson (NYSE: JNJ) today announced results for fourth-quarter and full-year 2025. “2025 was a catapult year for Johnson & Johnson, fueled by the strongest portfolio and pipeline in our history,” …
Alcon Completes $750 Million Share Repurchase Program
GENEVA–(BUSINESS WIRE)–Alcon Completes $750 Million Share Repurchase Program
Alcon Completes $750 Million Share Repurchase Program
GENEVA–(BUSINESS WIRE)–Alcon Completes $750 Million Share Repurchase Program
Artificial Iris Market Growth Forecast (2026-2032) Featuring Strategic Profiles of Leading Players Art Eyes, BrightOcular, Ophtec, REPER-NN, Spectrum Surgical, VEO Ophthalmics and More – ResearchAndMarkets.com
DUBLIN–(BUSINESS WIRE)–The “Artificial Iris Market – Global Forecast 2026-2032” has been added to ResearchAndMarkets.com’s offering. The Artificial Iris Market has shown significant growth, expanding from USD 17.71 million in 2024 to USD 19.31 millio…
Bausch + Lomb Will Release Fourth-Quarter and Full-Year 2025 Financial Results on Feb. 18
VAUGHAN, Ontario–(BUSINESS WIRE)–Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, will release its fourth-quarter and full-year 2025 financial results on Wednesday,…
Glaukos to Release Fourth Quarter and Full Year 2025 Financial Results after Market Close on February 17
ALISO VIEJO, Calif.–(BUSINESS WIRE)–Glaukos Corporation (NYSE: GKOS), an ophthalmic pharmaceutical and medical technology company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, plans to release fourt…
Emmecell Appoints Ramin Valian as Chief Executive Officer to Advance Magnetic Cell Delivery Platform
MENLO PARK, Calif.–(BUSINESS WIRE)–Emmecell announces the appointment of ophthalmology leader Ramin Valian as CEO.
Chicago Atlantic Provides $16.5 Million Term Loan to Ocular Science, Inc., a Leading Biotech Company Focused on Compounded Ophthalmic Products
CHICAGO–(BUSINESS WIRE)–Chicago Atlantic announced its role as sole arranger and administrative agent in the closing of a $16.5 million senior secured term loan for Ocular Science, Inc. (“Ocular Science”), an affiliate of OSRX, Inc. OSRX is a leading…
STAAR Surgical and Broadwood Partners Enter Into Cooperation Agreement
LAKE FOREST, Calif.–(BUSINESS WIRE)–STAAR Surgical Company (“STAAR” or the “Company”) (NASDAQ: STAA), the global leader in phakic IOLs with the EVO family of Implantable Collamer® Lenses (EVO ICL™) for vision correction, and Broadwood Partners, L.P. …
In Editorial, The New England Journal of Medicine Calls Science Corporation's PRIMA Implant "The First Treatment to Restore Vision" In Patients Suffering From Advanced Geographic Atrophy Due to Age-related Macular Degeneration
ALAMEDA, Calif.–(BUSINESS WIRE)–An editorial published today in The New England Journal of Medicine (NEJM) writes that Science Corporation’s PRIMA implant is the first treatment in clinical trials to successfully restore functional vision to certain …
Glaukos Announces Preliminary, Unaudited Fourth Quarter and Full Year 2025 Net Sales and Reaffirms 2026 Revenue Guidance
ALISO VIEJO, Calif.–(BUSINESS WIRE)–Glaukos Corporation (NYSE: GKOS), an ophthalmic pharmaceutical and medical technology focused on novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases, today announced its prelimina…